Hydrogel capsule, Gelesis100, reduces weight in overweight and obese subjects

June 23, 2014

A new "smart pill" called Gelesis100 safely leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, an international multicenter study finds. The three-month results of the First Loss Of Weight (FLOW) study were presented Sunday June 22, 2014 at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

Gelesis100 (formerly Attiva) is an orally administered capsulated device designed to cause weight loss by inducing satiety and reducing caloric intake, according to its manufacturer, Boston-headquartered Gelesis, which funded the FLOW study. In 128 nondiabetic , weight loss was most pronounced in those who had impaired levels of fasting blood glucose (sugar), also known as prediabetes, said Hassan Heshmati, MD, chief medical officer for Gelesis and a study co-investigator.

"Given the excellent safety profile observed in the FLOW study, Gelesis100 has the potential to fulfill the unmet need for a safe and effective weight loss agent. This is particularly impactful for individuals with mildly elevated (prediabetic subjects), for whom weight loss is particularly important because they are at increased risk for diabetes," Heshmati said.

This proof-of-concept study tested two doses of Gelesis100, a superabsorbent hydrogel, when taken twice a day with water before a meal. Forty-three subjects were randomly assigned to receive 2.25 grams (g) of Gelesis100 before lunch and dinner, another 42 subjects received 3.75 g of Gelesis100 and a third group of 43 subjects received a placebo capsule containing cellulose, a fiber which is used as a bulking agent. All subjects were instructed to eat 600 fewer calories a day. Neither the subjects nor the investigators knew which treatment they received during the 12 weeks of the study.

Among 125 subjects who weighed in at the start of the study and at least once after treatment, the average reductions in body weight by group at the end of treatment were as follows: 6.1 percent for 2.25 g of Gelesis100, 4.5 percent for 3.75 g of Gelesis100 and 4.1 percent for placebo. For subjects receiving the 2.25-g dose of Gelesis100, those with initial high fasting blood sugar (greater than the median level of 93 milligrams per deciliter, or mg/dL) had greater weight loss than did the others, losing 8.2 percent of their body weight on average, Heshmati reported.

The greatest weight loss reportedly occurred in prediabetic subjects whose starting fasting blood sugar level was 100 to 125.9 mg/dL. They lost an average of 10.9 percent of their .

Heshmati said he thinks the higher dose of Gelesis100 resulted in less because of lower tolerability leading to lower compliance with the study requirements. The most common side effects reported were bloating, flatulence, abdominal pain and diarrhea, which he said occurred less often with the smaller dose and were tolerable at that dose. No apparent serious problems occurred in either Gelesis100 group.

Gelesis100 capsules contain thousands of tiny hydrogel particles that expand in the stomach and mix with digested foods, said Gelesis' founder and chief executive officer, Yishai Zohar. He said this increases the volume and elasticity of the stomach and small intestine contents, inducing satiety and reducing . The particles are composed of two components which are used as food ingredients, but when cross-linked together form a unique structure that increases in volume. Gelesis100 does not create one big mass, rather thousands of small individual gel beads which have exactly the same elasticity (rigidity) as digested foods, but without any calories.

The first in a new class of weight management and obesity therapies, Gelesis100 will be regulated as a medical device if approved by the Food and Drug Administration, Zohar said.

Explore further: Diabetes drug appears to work for weight management, reversing prediabetes

Related Stories

Diabetes drug appears to work for weight management, reversing prediabetes

June 23, 2014
Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, ...

Diabetes drug, Liraglutide, improves risk factors for heart disease

June 23, 2014
Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, ...

Raising low vitamin D levels lowers risk of prediabetes progressing to diabetes

June 23, 2014
Vitamin D and calcium supplementation along with diet and exercise may prevent type 2 diabetes in prediabetic individuals who have insufficient vitamin D in their bodies, a study from India suggests. The results were presented ...

Sleeve gastrectomy surgery improves diabetes control better than medical care

June 23, 2014
Adults with Type 2 diabetes achieve better blood glucose (sugar) control two years after undergoing laparoscopic sleeve gastrectomy than do patients who receive standard medical diabetes care without this weight loss surgery, ...

Fast weight loss may mean muscle loss

May 29, 2014
(HealthDay)—If you lose weight too fast, you lose more muscle than when you shed excess pounds more slowly, a small study says.

Diabetes drug may spur weight loss in obese nondiabetics

May 30, 2014
(HealthDay)—A higher dose of the diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests.

Recommended for you

Are sugary drink interventions changing people's behaviour?

July 19, 2017
An evaluation of efforts designed to reduce how many sugary drinks we consume shows some success in changing younger people's habits but warns they cannot be the only way to cut consumption.

Young adult obesity: A neglected, yet essential focus to reverse the obesity epidemic

July 18, 2017
The overall burden of the U.S. obesity epidemic continues to require new thinking. Prevention of obesity in young adults, while largely ignored as a target for prevention and study, will be critical to reversing the epidemic, ...

Weight gain from early to middle adulthood may increase risk of major chronic diseases

July 18, 2017
Cumulative weight gain over the course of early and middle adulthood may increase health risks later in life, according to a new study led by researchers from Harvard T.H. Chan School of Public Health. They found that, compared ...

Study finds children carry implicit bias towards peers who are overweight

June 23, 2017
Even children as young as 9 years old can carry a prejudice against their peers who are overweight, according to a new study led by Duke Health researchers. They might not even realize they feel this way.

Mother's obesity boosts risk for major birth defects: study

June 15, 2017
Children of obese women are more likely to be afflicted by major birth defects, including malformations of the heart and genitals, according to a study published on Thursday.

New study finds more than 2 billion people overweight or obese

June 12, 2017
Globally, more than 2 billion children and adults suffer from health problems related to being overweight or obese, and an increasing percentage of people die from these health conditions, according to a new study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.